IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 3.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 876,599 shares of the company’s stock after purchasing an additional 27,690 shares during the quarter. Fisher Asset Management LLC owned approximately 1.01% of IDEAYA Biosciences worth $22,529,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. KBC Group NV grew its position in shares of IDEAYA Biosciences by 29.1% in the third quarter. KBC Group NV now owns 2,274 shares of the company’s stock valued at $72,000 after purchasing an additional 513 shares during the last quarter. Amalgamated Bank grew its position in shares of IDEAYA Biosciences by 22.9% in the third quarter. Amalgamated Bank now owns 2,840 shares of the company’s stock valued at $90,000 after purchasing an additional 530 shares during the last quarter. Rhumbline Advisers grew its position in shares of IDEAYA Biosciences by 0.5% in the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company’s stock valued at $2,919,000 after purchasing an additional 585 shares during the last quarter. US Bancorp DE grew its position in shares of IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after purchasing an additional 689 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of IDEAYA Biosciences by 35.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock valued at $94,000 after purchasing an additional 796 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on IDYA shares. Stephens reiterated an “overweight” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Wedbush reissued an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Leerink Partners downgraded shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $41.00 to $27.00 in a research note on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Leerink Partnrs downgraded shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Stock Down 7.0 %

NASDAQ:IDYA opened at $19.13 on Tuesday. The company has a market cap of $1.67 billion, a P/E ratio of -5.80 and a beta of 0.82. IDEAYA Biosciences, Inc. has a fifty-two week low of $18.93 and a fifty-two week high of $47.72. The firm’s 50 day moving average is $23.17 and its two-hundred day moving average is $28.45.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. Research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.